Domperidone Injection: Clinical Guidance
Critical Regulatory Status
Domperidone is NOT approved by the FDA for human use in the United States, and intravenous formulations are not available for human administration. 1 The drug is only approved for veterinary use (specifically for horses), and FDA labeling explicitly warns "Not for use in humans" 1. Any human use requires an expanded access investigational new drug (IND) application from the FDA 2.
Current Availability Crisis
The current supplier for domperidone under the FDA IND program in the United States is exiting the business and will no longer supply the medication 2. This makes domperidone increasingly unavailable even through the IND pathway.
Historical IV Domperidone Use (Research Context Only)
While IV domperidone is not available for current clinical use, historical research provides context:
Dosing in Research Studies
- Post-operative nausea/vomiting: 10-20 mg IV initially, followed by 10 mg every 6 hours 3, 4
- Pediatric antiemetic use: 1 mg/kg IV 5
- Pharmacokinetics: IV administration showed three-compartment model with 7.5-hour elimination half-life 6
Contraindications (from veterinary label, applicable to humans)
- Hypersensitivity to domperidone 1
- Prolonged QTc interval
- Clinically significant electrolyte disturbances
- History of dangerous arrhythmias
- Prolactinoma
- Pregnancy/breastfeeding 1
Current Clinical Practice: Oral Domperidone Only
For gastroparesis, the 2025 AGA guidelines suggest AGAINST domperidone as first-line treatment (conditional recommendation, very low quality evidence) 2. However, it may be considered in specific scenarios:
When to Consider (Oral Formulation via IND)
- Patients who experienced neurologic adverse effects with metoclopramide
- Patients with Parkinson's disease or other movement disorders
- Patients declining metoclopramide due to safety concerns 2
Mandatory Pre-Treatment Monitoring
Before initiating domperidone, obtain:
- Serum potassium and magnesium levels
- Baseline ECG with QTc interval measurement 2
Ongoing Monitoring Requirements
- Efficacy assessment: 4-8 weeks to determine continuation 2
- Safety monitoring: Serial serum potassium, magnesium, and ECG QTc intervals throughout treatment 2
- Long-term studies show mean treatment duration of 7.6 years in responders with dose averaging 36 mg/day orally 7
Cardiac Safety Considerations
- QTc prolongation is the primary cardiac concern
- In long-term studies with high-dose oral domperidone (40-120 mg/day), only 9.5% experienced meaningful QTc prolongation (>450 ms males, >470 ms females), which was asymptomatic 8
- Historical IV studies in children showed no serious dysrhythmias during 379 hours of monitoring 5
- One retrospective audit showed no significant QTc changes with domperidone during DHE infusion 9
Key Clinical Pitfalls
- Do not attempt to obtain IV domperidone - it is not available for human use in the US
- Do not use without IND approval - this is a federal requirement that is increasingly difficult to obtain given supply chain issues
- Do not skip baseline cardiac evaluation - QTc prolongation risk necessitates ECG screening
- Do not use in pregnancy - pregnant women should avoid handling even veterinary formulations due to effects on reproductive hormones 1
Bottom Line
Intravenous domperidone is not available or approved for human use in the United States. Even oral domperidone access through FDA IND programs is becoming unavailable due to supplier withdrawal. Clinicians should pursue alternative prokinetic and antiemetic therapies for gastroparesis and other indications where domperidone was historically considered.